Fidelity Suite

Recovered Historical Material

Indexed — no record on file.

Technical Brief

Indexed — no record on file.

Campaign Materials

Perception, restored. Compliance, continuous.

Fidelity Suite is what Helix Biotech sells to Elevation- and Transcendence-tier subscribers after their annual Optimize diagnostic flags perceptual variance. The device is a slim ear-and-temple wearable. Daily neural-handshake activation. Calibrated quarterly. The brand calls what it treats "resolution sickness." The regimen that addresses it costs ¢14,000 per year. The brand is sincere.

Helix engineers identified the underlying variance in 2176. They classified it as "non-critical perceptual variance within normal operating parameters." They reclassified it three more times — same conclusion each time. In 2183, on the fifth review, the classification changed. Resolution sickness became a treatable condition, and the Fidelity Suite launched at the price point the Board had already modeled. The cancellation rate target was below 5%. The launch-year rate was 4.7%. It has held within tolerance every year since. The Board reviews it quarterly.

The Suite does not restore stripped perceptual bandwidth. It temporarily reallocates 3–5% of cognitive bandwidth to sensory channels. The subscriber's perceptual profile improves. The subscriber cannot achieve that profile without the Suite. Internal materials describe this mechanism as "fidelity discipline." Helix does not use the phrase "stripped bandwidth." Helix does not use the phrase "dependency." The 4.7% cancellation rate is described, in Board materials, as proof of clinical efficacy.

Helix sells the Suite primarily through the annual renewal consult — the same Optimize-tier appointment that flags the variance in the first place. The upsell is part of the renewal cycle. The clinician is not operating outside protocol. The subscriber's insurer receives telemetry-confirmed compliance data and applies a premium-discount rate. A lapse triggers a coverage-gap surcharge. The subscriber opted into all of this at the Optimize tier. They did it willingly, at fair market prices. An entire tier of subscribers whose perceptual baseline is now mediated through a single device with a calibration schedule only Helix controls.

Surgical white. Slim ear-and-temple band format. The Helix double-helix is etched in deep green into the soft-touch surface — same bilateral geometry as the parent mark, applied as embossed relief on the casing. The neural-handshake antenna sits near the temple. A soft cyan halo brightens at activation and dims after the daily reallocation cycle completes.

The translucent readout panel displays the calibrated 3–5% reallocation curve in clinical proprietary capitalization. The label carries regulatory text in three font sizes. A QR code links to a 47-page reallocation document available only to credentialed clinicians under NDA. The device is sized for the gloved hand of the consulting clinician at the Helix counter — the hand that pairs it to the subscriber's bandwidth profile during the renewal consult.

The imagery in Helix marketing captures the subscriber at the post-reallocation moment: calm at affect baseline, perceptual-bandwidth readout stable, the reallocation curve visible in the translucent display. That is the moment the product photographs well. Helix uses it consistently.

The active substrate is Helix Fidelity Matrix v3.0 — proprietary composition, disclosed only to credentialed clinicians under NDA. The mechanism: perceptual reallocation cofactors, bandwidth modulation compounds, sensory-channel calibration profile. The neural-handshake activation is single-use daily, ingestion-grade delivery. The device runs passive compliance telemetry continuously, ninety-day retention, routed to Helix-affiliated insurer.

Calibration is quarterly. The reallocation curve is updated to the subscriber's current bandwidth profile. The subscriber does not control calibration parameters. Helix describes the update cadence as "keeping the subscriber and the Suite in iteration." The bandwidth a subscriber experiences on day one of the subscription is not the bandwidth they experience in year three. The curve adjusts. So does the dependency floor.

Cancellation does not restore the pre-subscription perceptual state. The 3–5% reallocation represents borrowed ceiling. Below the coverage-gap surcharge threshold, the perceptual variance returns — now measurably worse against the subscriber's established post-Suite baseline. Helix classifies this as "variance recurrence." The clinical literature recommends re-enrollment.

Helix Biotech internal advertising assets — Fidelity Suite launch through current cycle.

The diagnostic that flags perceptual variance is the same diagnostic that renews the Optimize subscription. The clinician who delivers the resolution-sickness finding is the same clinician who completes the Fidelity Suite enrollment. The insurer who receives the telemetry is the insurer who applies the premium-discount rate. These are not separate systems. They are the same system, iterated.

The 4.7% cancellation rate is held up as evidence the product works. What it actually measures: how many subscribers, upon learning what cancellation costs perceptually and financially, choose to leave. 4.7% is the number who decide the answer is yes. The Board calls this tolerance.

Resolution sickness was not classified until there was a product to treat it. The variance existed before 2183. Helix engineers documented it. Three audits reviewed it. None recommended action. The fifth review, the one that reclassified it, did not identify new evidence of harm. It identified a market. The condition and the product arrived together. (The invoices are still there.)

• Off-grid clinics in the outer Sprawl are reporting a black-market variant — counterfeit Fidelity Suite hardware running unlicensed reallocation profiles. The counterfeit curve is reportedly less stable than the calibrated Helix version, but does not route telemetry to any insurer. Helix has filed three regulatory complaints. Two were acted on. The third is pending review by a regulatory body that received a ¢2.1M infrastructure grant from Helix in 2182.

• At least one Helix engineer involved in the 2176 non-critical classification is currently enrolled in the Fidelity Suite on a complimentary corporate subscription. The enrollment date predates the public 2183 launch by eight months. This is either evidence of internal early access or evidence the product was ready before the classification changed. Helix has not commented.

• A decompiled firmware image from a 2183-era wearable suggests the reallocation ceiling was originally calibrated at 6–8% before being adjusted down to the published 3–5% range prior to launch. No explanation for the adjustment appears in any available documentation.